JMP Securities lowered the firm’s price target on Crinetics to $41 from $50 and keeps an Outperform rating on the shares. Crinetics Pharmaceuticals remains on track to report the first pivotal data for paltusotine in acromegaly in Q3, with steady pipeline progress providing a nice sequence of clinical readouts, the analyst tells investors in a research note. Management continues to execute well and its discovery engine and development strategy bring differentiated candidates into the clinic for rare endocrine disorders, and the firm is not concerned with a slight delay in PATHFNDR-2 timeline, JMP Securities says.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CRNX:
- Crinetics reports Q4 EPS (84c), consensus (82c)
- Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
- Crinetics to present corporate, clinical update at JPMorgan conference
